The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a ...

Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety ...

Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

South Korea’s Samsung Bioepis presented data, including the budget impact analysis on ustekinumab biosimilars’ cost savings ...

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...